• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Zenas BioPharma Inc.

    3/11/25 6:51:25 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZBIO alert in real time by email
    S-8 1 tm258608d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 11, 2025 

    Registration No. 333-

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, DC 20549

     

     

     

    FORM S-8 

    REGISTRATION STATEMENT 

    UNDER 

    THE SECURITIES ACT OF 1933

     

     

     

    ZENAS BIOPHARMA, INC. 

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   93-2749244

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

       

    852 Winter Street, Suite 250

    Waltham, MA

      02451
    (Address of Principal Executive Offices)   (Zip Code)

     

    Zenas BioPharma, Inc. 2024 Equity Incentive Plan 

    Zenas BioPharma, Inc. 2024 Employee Stock Purchase Plan 

    (Full titles of the plans)

     

     

     

    Leon O. Moulder, Jr. 

    Chief Executive Officer 

    Zenas BioPharma, Inc.

    852 Winter Street, Suite 250 

    Waltham, MA 02451 

    (Name and address of agent for service)

     

    (857) 271-2954 

    (Telephone number, including area code, of agent for service)

     

     

     

    Please send a copy of all communications to:

     

    Thomas Danielski 

    Nicholas Roper 

    Ropes & Gray LLP 

    Prudential Tower 

    800 Boylston Street 

    Boston, MA 02199-3600 

    617-951-7000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨   Accelerated filer   ¨
    Non-accelerated filer   x   Smaller reporting company   x
            Emerging growth company   x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

     

    EXPLANATORY NOTE 

    REGISTRATION OF ADDITIONAL SHARES

     

    Zenas BioPharma, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) for the purpose of registering (i) 2,089,670 additional shares of its common stock, par value $0.0001 per share (“Common Stock”), under the Zenas BioPharma, Inc. 2024 Equity Incentive Plan (the “2024 Plan”), pursuant to the provisions of the 2024 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2024 Plan on January 1, 2025, and (ii) 417,934 additional shares of Common Stock under the Zenas BioPharma, Inc. 2024 Employee Stock Purchase Plan (as amended and restated, the “ESPP”), pursuant to the provisions of the ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the ESPP on January 1, 2025. Pursuant to General Instruction E to Form S-8, the Registrant incorporates by reference, except to the extent supplemented, amended or superseded by the information set forth herein, into this Registration Statement the entire contents of its Registration Statement on Form S-8 (File No. 333- 282151) filed with the Commission on September 16, 2024.

     

    PART II 

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit    
       
    4.1   Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 16, 2024 and incorporated herein by reference).
       
    4.2   Amended and Restated Bylaws (previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 16, 2024 and incorporated herein by reference).
         
    4.3   Zenas BioPharma, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 4.6 to the registration statement on Form S-8 filed on September 16, 2024, File No. 333-282151).
       
    4.4   Zenas BioPharma, Inc. 2024 Employee Stock Purchase Plan, as amended and restated (incorporated by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K, filed on March 11, 2025).
       
    5.1*   Opinion of Ropes & Gray LLP
       
    23.1*   Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
       
    23.2*   Consent of Ropes & Gray LLP (included in the opinion filed as Exhibit 5.1)
       
    24.1*   Powers of Attorney (included on the signature page in Part II)
         
    107*   Filing Fee Table.

     

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Massachusetts, on this 11th day of March, 2025.

     

      ZENAS BIOPHARMA, INC.
         
      By: /s/ Leon O. Moulder, Jr.
        Name: Leon O. Moulder, Jr.
        Title:   Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Leon O. Moulder, Jr. and Joseph Farmer, and each of them singly, his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Zenas BioPharma, Inc. and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    * * * *

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature   Title   Date
             

    /s/ Leon O. Moulder, Jr.

    Leon O. Moulder, Jr.

     

    Chief Executive Officer and Director

    (Principal Executive Officer)

      March 11, 2025
             

    /s/ Jennifer Fox

    Jennifer Fox

     

    Chief Business Officer, Chief Financial Officer and Treasurer

    (Principal Accounting and Financial Officer)

      March 11, 2025
             

    /s/ Patricia Allen

    Patricia Allen

      Director   March 11, 2025
             

    /s/ James Boylan

    James Boylan

      Director   March 11, 2025
             

    /s/ Patrick Enright

    Patrick Enright

      Director   March 11, 2025
             

    /s/ Tomas Kiselak

    Tomas Kiselak

      Director   March 11, 2025
             

    /s/ Hongbo Lu, Ph.D.

    Hongbo Lu, Ph.D.

      Director   March 11, 2025
             

    /s/ Jake Nunn

    Jake Nunn

      Director  

    March 11, 2025

             

    /s/ John Orloff, M.D.

      Director   March 11, 2025
    John Orloff, M.D.        
             

    /s/ Ting Xiao

    Ting Xiao

      Director   March 11, 2025

     

     

     

    Get the next $ZBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBIO

    DatePrice TargetRatingAnalyst
    1/5/2026$19.00Overweight → Equal-Weight
    Morgan Stanley
    3/20/2025$35.00Outperform
    Wedbush
    2/4/2025$19.00Outperform
    Wolfe Research
    12/16/2024$30.00Buy
    H.C. Wainwright
    11/5/2024$34.00Buy
    Rodman & Renshaw
    10/8/2024$45.00Buy
    Guggenheim
    10/8/2024$40.00Overweight
    Morgan Stanley
    10/8/2024$35.00Buy
    Jefferies
    More analyst ratings

    $ZBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026

    - Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week data support the robust and durable activity of obexelimab and further validate its unique inhibitory mechanism of action - - Obexelimab was well tolerated, and no new safety signals were observed - WALTHAM, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients livin

    2/9/26 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management's presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 1:30 p.m. ET. A live webcast and archived replay of the Company's presentation can be accessed under "Events and Presentations" in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc.Zenas is a clinical-stage

    2/4/26 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on January 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase 100,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the "Inducement Grant"). The Ind

    1/16/26 4:15:00 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Moulder Leon O Jr bought $1,023,720 worth of shares (57,000 units at $17.96), increasing direct ownership by 16% to 423,155 units (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/3/26 4:30:13 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Moulder Leon O Jr bought $1,639,000 worth of shares (100,000 units at $16.39), increasing direct ownership by 38% to 366,155 units (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    1/9/26 9:42:58 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nunn Jason Raleigh bought $1,200,002 worth of shares (63,158 units at $19.00) (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    10/14/25 5:16:29 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Zenas BioPharma Inc.

    SCHEDULE 13G/A - Zenas BioPharma, Inc. (0001953926) (Subject)

    2/5/26 1:43:39 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B7 filed by Zenas BioPharma Inc.

    424B7 - Zenas BioPharma, Inc. (0001953926) (Filer)

    1/28/26 4:15:19 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by Zenas BioPharma Inc.

    SCHEDULE 13D - Zenas BioPharma, Inc. (0001953926) (Subject)

    1/14/26 4:30:54 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ZBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zenas Biopharma downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Zenas Biopharma from Overweight to Equal-Weight and set a new price target of $19.00

    1/5/26 3:43:35 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Zenas Biopharma with a new price target

    Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00

    3/20/25 8:00:59 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Zenas Biopharma with a new price target

    Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00

    2/4/25 7:13:29 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Moulder Leon O Jr bought $1,023,720 worth of shares (57,000 units at $17.96), increasing direct ownership by 16% to 423,155 units (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    2/3/26 4:30:13 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Moulder Leon O Jr bought $1,639,000 worth of shares (100,000 units at $16.39), increasing direct ownership by 38% to 366,155 units (SEC Form 4)

    4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    1/9/26 9:42:58 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Innocare Pharma Inc. claimed ownership of 5,000,000 shares (SEC Form 3)

    3 - Zenas BioPharma, Inc. (0001953926) (Issuer)

    10/15/25 6:12:28 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

    WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv

    4/7/25 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

    –Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s

    3/17/25 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    11/12/24 10:40:28 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    10/21/24 4:18:16 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zenas BioPharma Inc.

    SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

    9/25/24 6:00:11 PM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZBIO
    Financials

    Live finance-specific insights

    View All

    Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

    - Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically significant activity on all four key secondary efficacy endpoints - - Obexelimab was well tolerated and no new safety signals were observed - - Zenas anticipates submitting a Biologics License Application (BLA) to the FDA in the second quarter of 2026 and a Marketing Authorization Application (MAA) to the EMA in the second half of 2026 - - Zenas to host a conference call today, January 5, 2026, at 8:00 a.m. ET - WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc

    1/5/26 7:05:00 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

    Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO

    9/2/25 7:15:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

    - Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ:ZBIO), and Royalty Pharma plc (NASDAQ:RPRX) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are very pleased to partner with Royalty Pharma as we rapidly advance our broad obexelimab program through late-stage development

    9/2/25 7:05:00 AM ET
    $RPRX
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care